{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:13:09Z","timestamp":1790363589728,"version":"4.1.0"},"reference-count":30,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Reactive arthritis (ReA) is a spondyloarthritis triggered by a bacterial infection. In cases where nonsteroidal antiinflammatory drugs and conventional synthetic disease-modifying antirheumatic drugs have failed, biologics such as tumor necrosis factor inhibitors (TNFi) have been used. However, limited evidence exists of the efficacy and safety of these drugs in ReA. We report on Icelandic patients with ReA who have been treated with TNFi, their characteristics, outcomes, and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We conducted an observational cohort study using the Icelandic nationwide database of biologic therapy (ICEBIO) supplemented with a retrospective study of electronic health record (EHR) data. Drug efficacy was assessed using disease activity scores and standardized questionnaires within ICEBIO; safety was assessed using ICEBIO and EHR data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Thirty-eight patients with ReA were registered in the database. Eight were given TNFi within 1 year of symptom onset. At 6 and 18 months, there was a significant reduction in C-reactive protein (CRP), tender and swollen joints, visual analog scale for pain and fatigue, 28-joint count Disease Activity Score 28 based on CRP, Clinical Disease Activity Index, and Health Assessment Questionnaire scores. Seventy-one to 90% of patients were considered treatment responders. Two patients were able to stop biologics owing to remission. During the 303 patient-years (mean 8, range 1\u201315) biologics were given, 6 hospital admissions for infections were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>TNFi are safe and effective in ReA, but treatment tends to be prolonged. Further clinical trials are urgently needed in ReA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.191307","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T17:25:18Z","timestamp":1580577918000},"page":"1575-1581","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland"],"prefix":"10.3899","volume":"47","author":[{"given":"Bjarni","family":"Thorsteinsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arni J.","family":"Geirsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-1674","authenticated-orcid":false,"given":"Niels S.","family":"Krogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-6505","authenticated-orcid":false,"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2020,2,1]]},"reference":[{"key":"2022062017050783000_47.10.1575.1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740500202540"},{"key":"2022062017050783000_47.10.1575.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.005"},{"key":"2022062017050783000_47.10.1575.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1991.tb03845.x"},{"key":"2022062017050783000_47.10.1575.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70039-9"},{"key":"2022062017050783000_47.10.1575.5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s10067-013-2247-x","article-title":"Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study","volume":"32","author":"Uotila","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2022062017050783000_47.10.1575.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350210"},{"key":"2022062017050783000_47.10.1575.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6764.1299"},{"key":"2022062017050783000_47.10.1575.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.7.565"},{"key":"2022062017050783000_47.10.1575.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390725"},{"key":"2022062017050783000_47.10.1575.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340103"},{"key":"2022062017050783000_47.10.1575.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.27394"},{"key":"2022062017050783000_47.10.1575.12","first-page":"1065","article-title":"Reactive arthritis: current treatment challenges and future perspectives","volume":"37","author":"Lucchino","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022062017050783000_47.10.1575.13","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C"},{"key":"2022062017050783000_47.10.1575.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391211"},{"key":"2022062017050783000_47.10.1575.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh323"},{"key":"2022062017050783000_47.10.1575.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21323"},{"key":"2022062017050783000_47.10.1575.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.30272"},{"key":"2022062017050783000_47.10.1575.18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jbspin.2016.02.022","article-title":"Anti-TNF treatment of reactive arthritis. A monocentric experience","volume":"84","author":"Brinster","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2022062017050783000_47.10.1575.19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jbspin.2017.01.013","article-title":"A bicentre retrospective study of features and outcomes of patients with reactive arthritis","volume":"85","author":"Courcoul","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2022062017050783000_47.10.1575.20","first-page":"1068","article-title":"The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials","volume":"36","author":"Runarsdottir","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2022062017050783000_47.10.1575.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu252"},{"key":"2022062017050783000_47.10.1575.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2022062017050783000_47.10.1575.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032318"},{"key":"2022062017050783000_47.10.1575.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2022062017050783000_47.10.1575.25","first-page":"2185","article-title":"On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th international workshop on reactive arthritis, Berlin, Germany, July 3","volume":"27","author":"Braun","year":"2000","journal-title":"J Rheumatol"},{"key":"2022062017050783000_47.10.1575.26","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","article-title":"Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study","volume":"46","author":"Aaltonen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2022062017050783000_47.10.1575.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.148"},{"key":"2022062017050783000_47.10.1575.28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21649"},{"key":"2022062017050783000_47.10.1575.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123582"},{"key":"2022062017050783000_47.10.1575.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh225"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.191307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:10:07Z","timestamp":1655770207000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.191307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,1]]},"published-print":{"date-parts":[[2020,10,1]]}},"alternative-id":["10.3899\/jrheum.191307"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.191307","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}